The Boryung Pharmaceutical’s Kanarb made a clinical procedure with the PMDA to challenge the Japanese market
Boryung Pharmaceutical (President Tae-hong Choi) took the first step to expand to Japan by holding a meeting to make a clinical procedure for an approval of Kanarb on the 19th with the Pharmaceuticals and Medical Devices Agency (PMDA), the Department of Health and Human Services, Japan.
Although...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
